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Material and Methods: Chemically synthesized, RGD-/PEG- 
functionalized gold nanoparticles (RGD:AuNP; ≈2 -3 nm) were 
characterized using STEM, TEM, and LIBS imaging. Following 
clonogenic assay, radiation damage was induced in Panc1 
xenografts with 10 Gy and 220 kVp (Xtrahl, Inc). γ-H2AX, 3D-
(confocal) vessel imaging and IHC were performed. 
 
Results: Tumor vessel-targeted gold nanoparticles were 
subjected to conformal image-guided irradiation in Panc-1 
tumor xenograft to induce tumor vascular disruption. By 
specifically targeting the early angiogenic tumor 
endothelium, RGD:AuNP circumvent the dense stromal 
diffusion pathways that often limits the penetration and 
permeation of anti-cancer drugs/ nanoparticles to the cancer 
cells - a limitation of current radiosensitization approaches. 
In vitro testing in HUVEC displayed ≥3 -fold difference 
(***P<0.0001) in radiation damage in the +RGD:AuNP/+IR 
compared to the controls. More to it, the sub-millimeter 
accuracy of image-guided radiation therapy facilitated 
improved therapeutic efficacy (95%-100% tumor dose 
distribution) and less off-target toxicities. Quantification of 
the DNA-strand breaks (by γH2AX) showed ≈3 -fold increase 
(P<0.001) in the radiation specific DNA damage in the 
'nanoparticle-radiation' cohort (+RGD:AuNP/+IR: 57%) 
compared to the 'radiation' group (−RGD:AuNP/+IR:19%) and 
almost ≈10 -fold difference (P<0.001) compared to 
(+RGD:AuNP/−IR: 6% and −RGD:AuNP/−IR: 6%). 
 
Conclusion: This dual-targeting strategy holds great 
translational potential in radiation oncology. The resulting 
vascular disruption substantially improved the therapeutic 
outcome and subsidized the radiation/ nanoparticle toxicity, 
extending its utility to intransigent/ non-resectable tumors 
that barely respond to standard therapies. This abstract 
presents the first in-depth experimental investigation of 
tumor vascular disruption with nanoparticles, a novel 
strategy in radiation therapy. 
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Purpose or Objective: Inhibition of checkpoint kinases Wee1 
or Chk1 causes G2-checkpoint abrogation and mitotic 
catastrophe, particularly in p53 defective tumors. Based on 
this, Wee1 and Chk1 inhibitors are currently in clinical trials, 
combined with radiation or chemo-therapy. However, our 
previous work has shown that inhibition of Wee1 or Chk1 also 
causes DNA breakage in S-phase, largely due to high Cyclin-
Dependent-Kinase (CDK)-activity followed by unscheduled 
replication initiation. Furthermore, recent work by others has 
shown synergistic anti-cancer effects after combined Wee1 
and Chk1 inhibition. The aim of this study was to investigate 
whether S-phase DNA damage may contribute to the 
synergistic effects after combined Chk1/Wee1 inhibition. 
 
Material and Methods: Osteosarcoma U2OS and lung cancer 
A549, H460 and H1975 cells were exposed to the Wee1 
inhibitor MK1775 and/or the Chk1 inhibitors AZD7762, 
LY2606368, MK8776 and UCN01. The DNA damage marker 
gH2AX was analyzed in S-phase cells by flow cytometry. DNA 
damage signaling and inhibitory phosphorylation of CDK1 and 
CDK2 were examined by immunoblotting, and cell survival by 
clonogenic survival assays. CDK activity was measured in S-
phase cells by a novel flow cytometry barcoding method. In 
this method, CDK-dependent phosphorylations (antibodies to 
phospho-BRCA2 S3291, phospho-bMyb T487 and phospho-
Mpm2) versus DNA content (Hoechst staining) were examined 
in individual cells. Barcoding with Pacific Blue was included 
to reduce sample-to-sample variations. Loading of the 
replication initiation factor CDC45 was measured by a similar 
flow cytometry method and by immunoblotting after removal 
of unbound proteins by extraction with salt and detergent. 
 
Results: We observed a strong synergy in induction of S-phase 
damage after combined Wee1 and Chk1 inhibition. Also, 
clonogenic survival was strongly decreased after the 
combined treatment. Surprisingly, this synergy could not be 
explained by increased CDK-activity, as S-phase CDK-activity 
did not correlate with induction of DNA damage after Wee1 
and Chk1 inhibition. Wee1 inhibition caused a bigger increase 
in CDK-activity than Chk1 inhibition. However, Chk1 
inhibition caused more S-phase damage and loading of the 
replication factor CDC45. The combination of Wee1 and Chk1 
inhibitors further increased the CDC45 loading, and the 
extent of CDC45 loading correlated with DNA damage 
induction. 
 
Conclusion: We have shown for the first time that combined 
Wee1 and Chk1 inhibition causes synergistic S-phase DNA 
damage, due to distinct effects of Wee1 and Chk1 kinases in 
regulation of CDK activity and CDC45 loading, respectively. 
This synergy can explain the synergistic anti-cancer effects 
obtained by simultaneous Chk1/Wee1 inhibition. We propose 
that combined Chk1/Wee1 inhibition may be useful together 
with radiation therapy to eliminate radioresistant S-phase 
cells. 
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Purpose or Objective: Purpose: Glioblastoma demonstrates 
progression of disease within the high dose region of 
radiotherapy, in nearly all cases. The physiologic response 
within glioblastoma to radiation is in part dependent upon a 
pro-survival signaling. GRP78 was first described to regulate 
cellular stresses, including hypoglycemia, hypoxia and the ER 
stress response. GRP78 is an important regulator of cell 
stress, and binds to several pro-survival proteins. Antagonists 
to GRP78 include Kringle-5 and PAR4 which induce apoptosis 
in tumor vasculature endothelium and cancer cells. The 
molecular events that result from the ER stress response can 
enhance cell viability. GRP78 is overexpressed in poor 
prognosis cancers and is a molecular therapeutic target in 
poorly differentiated cancers. 
 
Material and Methods: Methods: We studied radiation 
induction of GRP78 by western immunoblot and flow 
cytometry. We used siRNA to knock down GRP78 in human 
GBM and NSCLC cell lines. In order to study the potential 
relationship between radiation dose and induction of ATF6 
activity, we treated D54 cells with 3 Gy and 6 Gy and 
analyzed GRP78 protein expression 48h after irradiation. We 
utilized Anti-GRP78 antibodies administered IV to mouse 
models of human cancer xenografts. We measured tumor 
growth delay using subcutaneous implants of human cancer 
xenografts. 
 
Results: Results: We found that radiation induces the 
expression of GRP78 in glioblastoma. Antibodies to GRP78 
enhanced radiation-induced cytotoxicity in glioblastoma but 
not normal cells. We found that radiation induced GRP78 
expression is regulated through the ER stress response, and 
that ATF6 is responsible for the transcriptional induction of 
GRP78. Knockdown of ATF6 abrogates GRP78 induction and 
enhanced cytotoxicity from radiation. Moreover interruption 
of GRP78 signaling enhances therapeutic effects of radiation. 
GRP78 antibodies enhanced cytotoxicity from radiation in 
human glioblastoma and NSCLC cell lines. We found that the 
levels of GRP78 protein were elevated at the 48 and 72h time 
points. Knockdown of ATF6 was sufficient to abrogate GRP78 
induction. We observed dose dependent increases in GRP78 
levels, which were reproducible when the experiment was 
repeated with LN827 cells. Similar changes were observed in 
GRP78 mRNA levels 48h after IR, where a 75% and 100% 
increase was observed in D54. Anti-GRP-78 antibodies bind 
specifically to irradiated cancers enhanced the efficacy of 
